Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
FLT3 N676D + FLT3 Y842C
Cancer:
Acute Myelogenous Leukemia
Drug:
Vanflyta (quizartinib)
(
FLT3 inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
New
Source:
Clin Cancer Res
Title:
Reversal of Acquired Drug Resistance in FLT3-mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
Excerpt:
AC220 demonstrated a similar pattern of resistance as observed with sorafenib treatment (Fig. 2A).
DOI:
https://dx.doi.org/10.1158%2F1078-0432.CCR-13-2052
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.